Search Result

Results for "

TLR7+agonist

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Payload (3) Aldehyde Oxidase (AO) (1) Apoptosis (2) Autophagy (10) Drug Derivative (1) Drug Intermediate (1) Drug-Linker Conjugates for ADC (2) EGFR (2) ERK (1) HBV (1) HCV (2) HSV (10) IFNAR (4) IKK (1) Influenza Virus (2) Interleukin Related (4) Isotope-Labeled Compounds (2) MAPKAPK2 (MK2) (1) MyD88 (1) NF-κB (1) NO Synthase (1) NOD-like Receptor (NLR) (1) Nucleoside Antimetabolite/Analog (5) p38 MAPK (1) PD-1/PD-L1 (1) PROTACs (1) Reference Standards (6) SARS-CoV (11) TNF Receptor (6) Toll-like Receptor (TLR) (73)
By Research Areas:	Cancer (49) Infection (22) Inflammation/Immunology (48) Neurological Disease (3)
Click Chemistry:	Alkynes (1)
Oligonucleotides:	Adjuvant (1)

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0180

Imiquimod Maximum Cited Publications 58 Publications Verification R 837	Toll-like Receptor (TLR) Autophagy SARS-CoV HSV	Infection Inflammation/Immunology Cancer
Imiquimod (R 837), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19 .

HY-B0180A

Imiquimod hydrochloride Maximum Cited Publications 58 Publications Verification R 837 hydrochloride	Toll-like Receptor (TLR) Autophagy SARS-CoV HSV	Infection Neurological Disease Inflammation/Immunology Cancer
Imiquimod hydrochloride (R 837 hydrochloride), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod hydrochloride exhibits antiviral and antitumor effects in vivo. Imiquimod hydrochloride can be used for the research of external genital, perianal warts, cancer and COVID-19 .

HY-111358

TLR7 agonist 1	Toll-like Receptor (TLR)	Inflammation/Immunology
TLR7 agonist 1 is a selective *TLR7* agonist with an LEC value of 90 nM. TLR7 agonist 1 activates downstream immune regulation and shows no activity against TLR8. TLR7 agonist 1 induces endogenous IFN-α production in mice .

HY-117602

TLR7 agonist 3 1 Publications Verification	Toll-like Receptor (TLR)	Neurological Disease Inflammation/Immunology Cancer
TLR7 agonist 3 (compound 2) is a *TLR7* agonist and can be used for the stuy of cancers .

HY-103039

TLR7 agonist 2 1 Publications Verification	Toll-like Receptor (TLR)	Inflammation/Immunology
TLR7 agonist 2 is a potent and selective Toll-like Receptor 7 (TLR7) agonist with a LEC of 0.4 μM.

HY-115400

1V209 4 Publications Verification TLR7 agonist T7	Toll-like Receptor (TLR)	Cancer
1V209 (TLR7 agonist T7) is a Toll-like receptor 7 (TLR7) agonist and has anti-tumor effects. 1V209 can be conjugated with various polysaccharides to improve its water solubility, and enhance its efficacy, and maintain low toxicity .

HY-108472

Loxoribine 7-Allyl-8-oxoguanosine; RWJ 21757	Toll-like Receptor (TLR) Influenza Virus	Infection Cancer
Loxoribine (7-Allyl-8-oxoguanosine) is a guanosine analog with anti-viral and anti-tumor activities. Loxoribine is an orally bioavailable and selective Toll-like receptor (TLR) 7 agonist .

HY-W008634

Bropirimine 2 Publications Verification U-54461; U-54461S; PNU-54461	Toll-like Receptor (TLR)	Cancer
Bropirimine (U-54461; U-54461S; PNU-54461) is an orally active *TLR7* agonist. Bropirimine inhibits RANKL-induced osteoclast differentiation of mouse bone marrow-derived macrophages (BMMs). Bropirimine exhibits dose-dependent direct inhibitory effects on colony formation of cultured KK-47 and 724 cells. Bropirimine can be used for the study of cancers and bone metabolic disorders such as osteoporosis .

HY-111582

BBIQ	Toll-like Receptor (TLR)	Inflammation/Immunology
BBIQ is a imidazoquinoline compound and a potent and selectively toll-like receptor 7 (TLR7) agonist with an EC₅₀ of 59.1 nM for human TLR7. BBIQ is a powerful vaccine adjuvant that enhances innate immune responses .

HY-100176

PF-4878691 3M-852A	Toll-like Receptor (TLR) Apoptosis TNF Receptor HCV Interleukin Related	Infection Inflammation/Immunology Cancer
PF-4878691 (3M-852A) is an orally active *TLR7* agonist. PF-4878691 has the innate immune response activity, antiviral efficacy against HCV, and can be used for the research of cancer .

HY-110120

DSR-6434 1 Publications Verification	Toll-like Receptor (TLR)	Cancer
DSR-6434 is a potent and selective Toll-like receptor 7 (TLR7) agonist, with EC₅₀s of 7.2 nM and 4.6 nM for human and mice *TLR7*, respectively. DSR-6434 has a strong antitumor effect .

HY-B0180B

Imiquimod maleate Maximum Cited Publications 58 Publications Verification	Toll-like Receptor (TLR) Autophagy SARS-CoV HSV	Infection Neurological Disease Inflammation/Immunology Cancer
Imiquimod maleate (R 837 maleate), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod maleate exhibits antiviral and antitumor effects in vivo. Imiquimod maleate can be used for the research of external genital, perianal warts, cancer and COVID-19 .

HY-160715

BNT411	Toll-like Receptor (TLR)	Cancer
BNT411 is a selective *TLR7* agonist that can induce the release of IFNa both in vivo and in vitro. BNT411 has anticancer activity and can be used in cancer research, including non-small cell lung cancer, pancreatic cancer, and untreated extensive-stage small cell lung cancer (ES-SCLC) .

HY-125390

SM-360320 CL-087	Toll-like Receptor (TLR)	Inflammation/Immunology Cancer
SM-360320 (CL-087) is a potent, orally active *TLR7* agonist. SM-360320 is a immuno-modulator and exerts an antitumor effect. SM-360320 can act in synergy with DNA vaccines leading to an enhanced Th1 antibody response . SM-360320 can inhibit HCV replication in hepatocytes via a type I IFN-independent mechanism in addition to its IFN-mediated activity .

HY-145961

TLR7 agonist 4	Toll-like Receptor (TLR) TNF Receptor	Cancer
TLR7 agonist 4 is a *TLR7* agonist with pro-inflammatory cytokine-stimulating activity. TLR7 agonist 4 modulates *TLR7* activity to stimulate the production of pro-inflammatory cytokines. TLR7 agonist 4 stimulates mouse bone marrow-derived macrophages to produce the pro-inflammatory cytokine TNFα. TLR7 agonist 4 can be conjugated with antibodies to form conjugates. TLR7 agonist 4 is applicable to cancer research .

HY-156174

E104	Toll-like Receptor (TLR) ADC Payload	Cancer
E104 (compound 1) is a potent and selective *TLR7* agonist. E104 can be delivered by antibody-drug conjugate (ADC) technology to elicit potent anticancer activity. E104 induces the activation of mouse macrophages and hPBMCs .

HY-145592

Ruzotolimod RO7020531; RG7854	Toll-like Receptor (TLR) SARS-CoV HBV	Infection
Ruzotolimod (RO7020531) is an orally active *TLR7* agonist. Ruzotolimod inhibits WHV viral replication and, in combination with RO-7049389 (HY-145579), inhibits AAV-HBV viral load. Ruzotolimod can be used to study infection with COVID-19 or SARS-CoV-2 .

HY-118250

GSK2245035 2 Publications Verification	Toll-like Receptor (TLR) IFNAR TNF Receptor	Inflammation/Immunology
GSK2245035 is a highly potent and selective intranasal Toll-Like receptor 7 (TLR7) agonist with preferential Type-1 interferon (IFN)-stimulating properties. GSK2245035 has pEC₅₀s of 9.3 and 6.5 for IFNα and TFNα. GSK2245035 effectively suppresses allergen-induced Th2 cytokine production in human peripheral blood cell cultures. GSK2245035 is used for asthma .

HY-153070

TLR7 agonist 5	Toll-like Receptor (TLR)	Inflammation/Immunology
TLR7 agonist 5 (compound IIb-11) is an *TLR7* agonist with an EC₅₀ value of ~4 nM .

HY-153073

TLR7 agonist 8	Toll-like Receptor (TLR) Interleukin Related	Infection Inflammation/Immunology Cancer
TLR7 agonist 8 is a *TLR7* agonist with an EC₅₀ of 0.12 nM for TLR7 and an EC₅₀ of 0.76 nM for IL-6 induction. TLR7 agonist 8 can be used for research on diseases such as fibrosis, inflammatory diseases, cancer, or pathogen infections .

HY-158694A

TLR7 agonist 20 hydrochloride	Toll-like Receptor (TLR)	Inflammation/Immunology
TLR7 agonist 20 hydrochloride is a selective Toll-like receptor 7 (TLR7) agonist with an EC₅₀ of 0.22 μM. TLR7 agonist 20 hydrochloride, as an immunostimulant and vaccine adjuvant, enhances the production of anti-spike protein antibodies, increases IgG2b and IgG2c levels, and thereby drives Th1-type immune responses in mice. TLR7 agonist 20 hydrochloride can be used in studies related to non-inflammatory potent vaccine adjuvants .

HY-123291

SM-276001	Toll-like Receptor (TLR) IFNAR	Inflammation/Immunology Cancer
SM-276001 is a potent selective *TLR7* agonist that can induce antitumor immune responses. SM-276001 is an orally active interferon (IFN) inducer .

HY-163398

TLR7-IN-1	Toll-like Receptor (TLR)	Cancer
TLR7-IN-1 (Compound 16-A) is a *TLR7* agonist with an EC₅₀ of 0.001 μM. TLR7-IN-1 is applicable to cancer-related research .

HY-156693A

MTvkPABC-P5 TFA	Toll-like Receptor (TLR)	Inflammation/Immunology
MTvkPABC-P5d TFA, a *TLR7* agonist, is an immune stimulant. MTvkPABC-P5d TFA can be used for synthesis of immune-stimulating antibody conjugates (ISACs) .

HY-153071

TLR7 agonist 6	Toll-like Receptor (TLR)	Inflammation/Immunology
TLR7 agonist 6 (compound IIb-19) is an *TLR7* agonist with an EC₅₀ value of 1.0 nM .

HY-173070

TLR7 agonist 29	Toll-like Receptor (TLR) IFNAR PD-1/PD-L1 ADC Payload	Inflammation/Immunology Cancer
TLR7 agonist 29 (Compound 1) is the agonist for *TLR7* with an EC₅₀ of 5.2 nM for human TLR7 (EC₅₀ for mouse TLR7 is 48.2 nM). TLR7 agonist 29 activates bone marrow-derived macrophages (BMDMs), stimulates myeloid cells in the tumor microenvironment, promotes the expression of PD-L1, CD86 and IFN-α. TLR7 agonist 29 can be used as payload for synthesis of ADC .

HY-B0180R

Imiquimod (Standard) R 837 (Standard)	Reference Standards Toll-like Receptor (TLR) Autophagy SARS-CoV HSV	Infection Inflammation/Immunology Cancer
Imiquimod (Standard) is the analytical standard of Imiquimod. This product is intended for research and analytical applications. Imiquimod (R 837), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19 .

HY-145960

*MC-Val-Cit-PAB-Amide-TLR7 agonist* 4**	EGFR Toll-like Receptor (TLR)	Inflammation/Immunology
MC-Val-Cit-PAB-Amide-TLR7 agonist 4 (example 15) is a *HER2-TLR7* and HER2-TLR8 immune agonist conjugate .

HY-179007

TLR7 agonist 31	Toll-like Receptor (TLR)	Cancer
TLR7 agonist 31 (Compound 116) is a *TLR7* agonist, with an EC₅₀ of 31 nM. TLR7 agonist 31 can be used in the research of cancer .

HY-173079

TLR7 agonist 30	Toll-like Receptor (TLR) Drug-Linker Conjugates for ADC	Cancer
TLR7 agonist 30 (compound 2) is an agent-linker conjugate for ADC. TLR7 agonist 30 contains a TLR7 agonist (compound 1) and a cleavable linker, and has potent anti-tumor activity .

HY-156177

TLR7 agonist 16	Toll-like Receptor (TLR)	Inflammation/Immunology
TLR7 agonist 16 (compound 16d) is a highly potent *TLR7* agonist with an EC₅₀ of 18 nM. TLR7 agonist 16 potently induces the activation of mouse macrophages and hPBMCs at low-nanomolar concentrations .

HY-156176

TLR7 agonist 15	Toll-like Receptor (TLR)	Inflammation/Immunology
TLR7 agonist 15 (compound 16b) is a highly potent *TLR7* agonist with an EC₅₀ of 18 nM. TLR7 agonist 15 potently induces the activation of mouse macrophages and hPBMCs at low-nanomolar concentrations .

HY-153072

TLR7 agonist 7	Toll-like Receptor (TLR)	Inflammation/Immunology
TLR7 agonist 7 (compound IIb-26) is an *TLR7* agonist with an EC₅₀ value of ~4 nM .

HY-168159

TLR7 agonist 27	Toll-like Receptor (TLR) NOD-like Receptor (NLR)	Inflammation/Immunology
TLR7 agonist 27 (compound 24) is a potent TLR7 agonist with an EC₅₀ of 238.1 nM. TLR7 agonist 27 shows weak agonistic activity against NOD2 (nucleotide-binding oligomerization domain 2) (EC₅₀ of 6.2 μM). TLR7 agonist 27 is a potent immunostimulant, and can be used as a vaccine adjuvant and/or immunotherapeutic .

HY-179275

TLR7 agonist 33	Toll-like Receptor (TLR)	Cancer
TLR7 agonist 33 (Compound 141) is a potent *TLR7* activator with an EC₅₀ of 1 nM. TLR7 agonist 33 can be used for cancer research .

HY-158694

TLR7 agonist 20	Toll-like Receptor (TLR)	Inflammation/Immunology
TLR7 agonist 20 is a selective Toll-like receptor 7 (TLR7) agonist with an EC₅₀ of 0.22 μM. TLR7 agonist 20, as an immunostimulant and vaccine adjuvant, enhances the production of anti-spike protein antibodies, increases IgG2b and IgG2c levels, and thereby drives Th1-type immune responses in mice. TLR7 agonist 20 can be used in studies related to non-inflammatory potent vaccine adjuvants .

HY-152726

TLR7 agonist 9	Toll-like Receptor (TLR) Nucleoside Antimetabolite/Analog	Infection Cancer
TLR7 agonist 9 (compound 10) is an aonist of *TLR7. TLR7 agonist* 9 can be used for research of cancer and infectious disease . TLR7 agonist 9 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-139575

Guretolimod DSP-0509	Toll-like Receptor (TLR)	Inflammation/Immunology Cancer
Guretolimod (DSP-0509) is a Toll-like receptor 7 (TLR7) agonist .

HY-111786

LHC-165	Toll-like Receptor (TLR)	Cancer
LHC-165 is a *TLR7* agonist. LHC-165 has potential to used in study of solid tumors .

HY-179047

SMU-L11-R	Toll-like Receptor (TLR) MyD88 IKK p38 MAPK ERK TNF Receptor Interleukin Related	Inflammation/Immunology Cancer
SMU-L11-R is a selective *TLR7* agonist with an EC₅₀ of 0.012 μM for human TLR7. SMU-L11-R specifically activates TLR7, recruits MyD88, and triggers MAPK/NF-κB pathways, leading to TNF-α/IL-1β/IL-6 secretion in both mouse and human peripheral blood mononuclear cells. SMU-L11-R promotes M1-like macrophage polarization. SMU-L11-R exhibits excellent synergistic anti-tumor effects with PD-L1 inhibitors by upregulating CD8 ⁺T cells. SMU-L11-R shows potential in colorectal cancer studies .

HY-145960A

*MC-Val-Cit-PAB-Amide-TLR7 agonist* 4 formic**	EGFR Toll-like Receptor (TLR)	Inflammation/Immunology
MC-Val-Cit-PAB-Amide-TLR7 agonist 4 formic (example 15) is a *HER2-TLR7* and HER2-TLR8 immune agonist conjugate .

HY-170899

TLR7 agonist 28	Toll-like Receptor (TLR)	Cancer
TLR7 agonist 28 (compound 3) is a potent TLR7 agonist. TLR7 agonist 28 can conjugat to antitumor monoclonal antibodies (mAbs) for cancer immunotherapy .

HY-168157

TLR7 agonist 26	Toll-like Receptor (TLR)	Inflammation/Immunology
TLR7 agonist 26 (Compound 4) is a potent Toll-like receptor 7 (TLR7) agonist, with an EC₅₀ of 225.5 nM. TLR7 agonist 26 shows immunopotentiating effects .

HY-162115

TLR7 agonist 17	Toll-like Receptor (TLR)	Cancer
TLR7 agonist 17 (compound 20) is a potent *TLR7* agonist with EC₅₀ values of 12 nM and 17 nM for hTLR7 and mTLR7, respectively. TLR7 agonist 17 shows anticancer activity .

HY-156175

TLR7 agonist 14	Toll-like Receptor (TLR)	Inflammation/Immunology
TLR7 agonist 14 (compound 17b) is a highly potent *TLR7* agonist with an EC₅₀ of 18 nM. TLR7 agonist 14 potently induces the activation of mouse macrophages and hPBMCs at low-nanomolar concentrations .

HY-161726

TLR7 agonist 23	Toll-like Receptor (TLR)	Inflammation/Immunology
TLR7 agonist 23 (compound 12b) is a potent Toll Like Receptor-7 (TLR7) agonist with a EC₅₀ of 0.15 uM. TLR7 agonist 23 can be used in the study of immunological diseases .

HY-162163

TLR7 agonist 19	Toll-like Receptor (TLR)	Cancer
TLR7 agonist 19 (Compound 14) is a Toll-like receptor 7 (TLR7) agonist with excellent pharmacokinetic properties and synergistic antitumor activity.

HY-162579

TLR7 agonist 22	Toll-like Receptor (TLR)	Inflammation/Immunology
TLR7 agonist 22 (Compound 11a) emerges as a selective *TLR7* agonist with an IC₅₀ value of 25.86 μM. TLR7 agonist 22 inhibits the cellular HBsAg secretion and effectively activates TLR7, thereby inducing the secretion of *TLR7*-regulated cytokines IL-12, TNF-αand IFN-αin human PBMC cells. TLR7 agonist 22 is a promising for research in the field of developing novel immunomodulatory anti-HBV agents .

HY-162116

TLR7 agonist 18	Toll-like Receptor (TLR)	Inflammation/Immunology Cancer
TLR7 agonist 18 (Compound 21a) is a selective Toll-like receptor 7 (TLR7) agonist with an EC₅₀ of 7.8 μM. TLR7 agonist 18 is not cytotoxic to hTLR7 cotransfected HEK293 cell lines and can induce the secretion of several cytokines, including IL-1β, IL-12p70, IL-8, and TNF-α. TLR7 agonist 18 can be used in vaccine, asthma, allergy and anti-cancer research .

HY-154271

TLR7 agonist 12	Nucleoside Antimetabolite/Analog	Cancer
TLR7 agonist 12 (example 20) is a *TLR7* agonist, also is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .

Cat. No.	Product Name	Chemical Structure

HY-B0180S1

Imiquimod-d9
Imiquimod-d₉ is deuterium labeled Imiquimod. Imiquimod (R 837), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19 .

HY-B0180S

Imiquimod-d6
Imiquimod-d₆ is the deuterium labeled Imiquimod. Imiquimod (R 837), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19 .

HY-B0180S2

Imiquimod-d7
Imiquimod-d₇ (R 837-d₇) is deuterium labeled Imiquimod. Imiquimod (R 837), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19 .

Cat. No.	Product Name		Classification

HY-154361

TLR7 agonist 13		Alkynes
TLR7 agonist 13 is a guanosine analog. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7) . TLR7 agonist 13 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Cat. No.	Product Name		Classification

HY-111582

BBIQ		Adjuvant
BBIQ is a imidazoquinoline compound and a potent and selectively toll-like receptor 7 (TLR7) agonist with an EC₅₀ of 59.1 nM for human TLR7. BBIQ is a powerful vaccine adjuvant that enhances innate immune responses .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: